deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02826161

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)

A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Sponsor: Sumitomo Pharma America, Inc.

Conditions Carcinoma, Non-Small-Cell Lung
Interventions Napabucasin Paclitaxel
Updated 17 times since 2017 Last updated: Nov 13, 2023 Started: Nov 30, 2016 Primary completion: Apr 24, 2017 Completion: Apr 24, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Change of treatment landscape and evolving standard of care

Other terminated trials from Sumitomo Pharma America, Inc.

More terminations from Sumitomo Pharma America, Inc.

Other Carcinoma, Non-Small-Cell Lung trials with similar outcome

Browse all Carcinoma, Non-Small-Cell Lung trials

Listed as NCT02826161, this PHASE3 trial focuses on Carcinoma, Non-Small-Cell Lung and remains terminated or withdrawn. Sponsored by Sumitomo Pharma America, Inc., it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Aug 2017 · 4 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Aug 2020 · 16 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Nov 2023 · 10 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Dec 2023 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Nov 2023 — Dec 2023 [monthly]

    Terminated PHASE3

  5. Jan 2023 — Nov 2023 [monthly]

    Terminated PHASE3

▶ Show 12 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE3

  2. May 2022 — Dec 2022 [monthly]

    Terminated PHASE3

  3. Dec 2021 — May 2022 [monthly]

    Terminated PHASE3

  4. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Terminated PHASE3

  6. Aug 2020 — Jan 2021 [monthly]

    Terminated PHASE3

  7. Apr 2019 — Aug 2020 [monthly]

    Terminated PHASE3

  8. Jun 2018 — Apr 2019 [monthly]

    Terminated PHASE3

  9. Aug 2017 — Jun 2018 [monthly]

    Terminated PHASE3

    Status: Recruiting → Terminated

  10. Apr 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  11. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sumitomo Pharma America, Inc.
Data source: Sumitomo Pharma America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations